Study analysis · Science translational medicine · 2023
Your gut bacteria could reveal Alzheimer's risk a decade before memory loss.
Older adults with early Alzheimer's brain changes have different gut bacteria, and a computer model using these bacteria was 78% accurate at identifying them, compared to 67% without the bacteria data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study took a snapshot of people's gut bacteria and compared those with early signs of Alzheimer's in their brain to those without. They found that the two groups had different types of bacteria. This tells us there might be a connection, but it doesn't tell us which came first or if one causes the other. It's like noticing that people who wear glasses often have books nearby – they might be related, but you can't say one causes the other just from that one moment.
What’s the bottom line?
Researchers looked at gut bacteria in older adults with normal memory. Some had early signs of Alzheimer's in their brains (detected by scans). They found that the types of bacteria in their gut were different from those without brain changes.
How strong is this study?
The scientists did a good job by carefully measuring many things like age, diet, and health conditions to make sure the differences they saw were really linked to the brain changes. But the study only looks at one point in time, so we don't know if the gut bacteria changed before or after the brain changes. Also, the group of people studied was not very big and came from just one research center, so we need more studies to be sure the results apply to everyone.
60 / 100
- COI disclosureconflicts of interest not disclosed
- Data availability+35/35
- Code availability+25/25
33 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=164)+11.2/20
- Follow-upno follow-up reported
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 544 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. Cross-sectional design measures exposure and outcome simultaneously, so temporal sequence cannot be established. Cannot determine whether microbiome changes precede or result from preclinical Alzheimer's pathology. Residual confounding may also influence associations.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding information provided in the text.
The study text does not include any disclosure statements regarding conflicts of interest, funding sources, or author affiliations. Therefore, the potential for undisclosed conflicts cannot be assessed.
Key takeaways
- 01
The study of 164 people found that certain gut bacteria were linked to early Alzheimer's brain changes.
- 02
A computer model using these bacteria could correctly identify 78% of cases, compared to 67% without them.
- 03
The improvement is modest but suggests stool samples might someday help screen for Alzheimer's risk.
Surprising findings
- Gut microbiome composition correlated with amyloid and tau pathology but not with markers of neurodegeneration.Most people think Alzheimer's is purely a brain disease, and that gut changes would be a late consequence. This suggests the microbiome may be involved early, before brain damage occurs.
- Adding microbiome features to a model without any AD biomarkers improved accuracy by 11.2%, but the gain was only 1.4% when amyloid biomarkers were included.It shows the gut bacteria are providing information that overlaps with amyloid, but they can't replace the gold standard. Still, when you don't have PET or CSF, they help a lot.
Practical takeaways
If you have a family history of Alzheimer's and can access it, consider participating in research studies that analyze stool samples to help advance early detection methods.
This is not a clinically validated test; it's still research. Do not make health decisions based on gut microbiome composition alone.
low confidenceMaintain a healthy gut microbiome through a high-fiber diet and probiotics, as general good health may reduce inflammation that contributes to Alzheimer's risk.
No specific probiotic or diet has been proven to prevent Alzheimer's. The study was observational and not interventional.
medium confidenceIf you're a content creator, use this study to explain the gut-brain axis and early Alzheimer's detection, but always emphasize the study limitations.
The study had modest sample size and corrections published; check the correction notices.
medium confidenceWhy this study matters
Gut Bacteria Change Early in Alzheimer's
In 164 cognitively normal older adults (mean age ~75), those with preclinical Alzheimer's (abnormal amyloid and tau) had distinct gut microbiome profiles (PERMANOVA P=0.036). The changes correlated with amyloid and tau, but not with neurodegeneration, suggesting the microbiome shift occurs early in the disease.
This means a simple stool test could potentially detect Alzheimer's risk years before symptoms appear, when interventions might be most effective.
Machine Learning Gets a Boost from Bacteria
Adding seven bacterial species to a Random Forest classifier improved accuracy by 11.2% (from 67.2% to 78.4%) when conventional Alzheimer's biomarkers (PET scans, spinal taps) were unavailable. The model only used demographics and clinical covariates plus stool data.
For people in rural areas or without access to expensive neuroimaging, a stool sample could become a low-cost screening tool to identify those needing further testing.
Specific Bacteria Linked to Preclinical AD
Five bacterial species were significantly associated with preclinical AD: Dorea formicigenerans (coefficient=0.661), Oscillibacter sp. 57_20 (0.512), Faecalibacterium prausnitzii (0.298), Coprococcus catus (0.190), and Anaerostipes hadrus (0.163). Some are typically anti-inflammatory, highlighting context-dependent roles.
The same bacteria can be protective or harmful depending on the host and disease stage – a reminder that microbiome science is nuanced.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Researchers looked at gut bacteria in older adults with normal memory. Some had early signs of Alzheimer's in their brains (detected by scans). They found that the types of bacteria in their gut were different from those without brain changes.
Research results
The study of 164 people found that certain gut bacteria were linked to early Alzheimer's brain changes. A computer model using these bacteria could correctly identify 78% of cases, compared to 67% without them.
What this means - more context
The improvement is modest but suggests stool samples might someday help screen for Alzheimer's risk.
To determine if gut microbiome composition differs in cognitively normal older adults with preclinical Alzheimer's disease (abnormal amyloid) and if microbiome features improve prediction of preclinical AD.
In 164 cognitively normal adults (49 with preclinical AD), gut microbiome taxonomic composition differed between groups (PERMANOVA P=0.036). Specific bacterial species were associated with preclinical AD. Adding microbiome features improved machine learning classifier accuracy by up to 11.2% when conventional biomarkers were unavailable.
Methods Used
Cross-sectional study of 164 cognitively normal older adults (mean age ~75); stool metagenomic sequencing; clinical covariates and diet accounted for; machine learning (Random Forest) with Boruta feature selection; validation on 65 participants.
Main Finding
Gut microbiome composition correlates with early Alzheimer's pathology (amyloid and tau) but not neurodegeneration; specific taxa (e.g., Dorea formicigenerans, Faecalibacterium prausnitzii) associated with preclinical AD; adding microbiome features improved prediction accuracy from 67.2% to 78.4% when conventional biomarkers unavailable.
Confidence Level
Moderate – cross-sectional, modest sample size, covariates and diet accounted for; validation subset; corrections published; readers should check correction notices.
Study Flags
Red Flags
- •Corrections/errata published; readers should check correction notices
- •Cross-sectional design cannot establish causality
- •Modest sample size (n=164) with validation subset (n=65)
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Gut microbiome composition correlated with amyloid and tau pathology but not with markers of neurodegeneration.
Most people think Alzheimer's is purely a brain disease, and that gut changes would be a late consequence. This suggests the microbiome may be involved early, before brain damage occurs.
Practical Takeaways
If you have a family history of Alzheimer's and can access it, consider participating in research studies that analyze stool samples to help advance early detection methods.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 544 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Human Cross-Sectional
Subject
Moderate probability
on the GRADE evidence scale
This study took a snapshot of people's gut bacteria and compared those with early signs of Alzheimer's in their brain to those without. They found that the two groups had different types of bacteria. This tells us there might be a connection, but it doesn't tell us which came first or if one causes the other. It's like noticing that people who wear glasses often have books nearby – they might be related, but you can't say one causes the other just from that one moment.
Strengths
- Well-characterized cohort with detailed clinical, biomarker, and dietary data
- Adjustment for multiple covariates (age, APOE, BMI, diabetes, hypertension)
- Use of metagenomic sequencing for microbial profiling
Weaknesses
- Cross-sectional design precludes temporal inference
- Long intervals between stool collection and biomarker measurements (mean 2.4-2.8 years)
- Small sample size for machine learning validation (n=65)
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Researchers looked at gut bacteria in older adults with normal memory. Some had early signs of Alzheimer's in their brains (detected by scans). They found that the types of bacteria in their gut were different from those without brain changes.
Research results
The study of 164 people found that certain gut bacteria were linked to early Alzheimer's brain changes. A computer model using these bacteria could correctly identify 78% of cases, compared to 67% without them.
What this means - more context
The improvement is modest but suggests stool samples might someday help screen for Alzheimer's risk.
To determine if gut microbiome composition differs in cognitively normal older adults with preclinical Alzheimer's disease (abnormal amyloid) and if microbiome features improve prediction of preclinical AD.
In 164 cognitively normal adults (49 with preclinical AD), gut microbiome taxonomic composition differed between groups (PERMANOVA P=0.036). Specific bacterial species were associated with preclinical AD. Adding microbiome features improved machine learning classifier accuracy by up to 11.2% when conventional biomarkers were unavailable.
Methods Used
Cross-sectional study of 164 cognitively normal older adults (mean age ~75); stool metagenomic sequencing; clinical covariates and diet accounted for; machine learning (Random Forest) with Boruta feature selection; validation on 65 participants.
Main Finding
Gut microbiome composition correlates with early Alzheimer's pathology (amyloid and tau) but not neurodegeneration; specific taxa (e.g., Dorea formicigenerans, Faecalibacterium prausnitzii) associated with preclinical AD; adding microbiome features improved prediction accuracy from 67.2% to 78.4% when conventional biomarkers unavailable.
Confidence Level
Moderate – cross-sectional, modest sample size, covariates and diet accounted for; validation subset; corrections published; readers should check correction notices.
Study Flags
Red Flags
- •Corrections/errata published; readers should check correction notices
- •Cross-sectional design cannot establish causality
- •Modest sample size (n=164) with validation subset (n=65)
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Gut microbiome composition correlated with amyloid and tau pathology but not with markers of neurodegeneration.
Most people think Alzheimer's is purely a brain disease, and that gut changes would be a late consequence. This suggests the microbiome may be involved early, before brain damage occurs.
Practical Takeaways
If you have a family history of Alzheimer's and can access it, consider participating in research studies that analyze stool samples to help advance early detection methods.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 544 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Human Cross-Sectional
Subject
Moderate probability
on the GRADE evidence scale
This study took a snapshot of people's gut bacteria and compared those with early signs of Alzheimer's in their brain to those without. They found that the two groups had different types of bacteria. This tells us there might be a connection, but it doesn't tell us which came first or if one causes the other. It's like noticing that people who wear glasses often have books nearby – they might be related, but you can't say one causes the other just from that one moment.
Strengths
- Well-characterized cohort with detailed clinical, biomarker, and dietary data
- Adjustment for multiple covariates (age, APOE, BMI, diabetes, hypertension)
- Use of metagenomic sequencing for microbial profiling
Weaknesses
- Cross-sectional design precludes temporal inference
- Long intervals between stool collection and biomarker measurements (mean 2.4-2.8 years)
- Small sample size for machine learning validation (n=65)
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The scientists did a good job by carefully measuring many things like age, diet, and health conditions to make sure the differences they saw were really linked to the brain changes. But the study only looks at one point in time, so we don't know if the gut bacteria changed before or after the brain changes. Also, the group of people studied was not very big and came from just one research center, so we need more studies to be sure the results apply to everyone.
60 / 100
- COI disclosureconflicts of interest not disclosed
- Data availability+35/35
- Code availability+25/25
33 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=164)+11.2/20
- Follow-upno follow-up reported
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 544 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. Cross-sectional design measures exposure and outcome simultaneously, so temporal sequence cannot be established. Cannot determine whether microbiome changes precede or result from preclinical Alzheimer's pathology. Residual confounding may also influence associations.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding information provided in the text.
The study text does not include any disclosure statements regarding conflicts of interest, funding sources, or author affiliations. Therefore, the potential for undisclosed conflicts cannot be assessed.